NCT02423577 is a Phase 2 clinical trial of FF-3 dry powder in Influenza, sponsored by Autoimmune Technologies, LLC.

Who is sponsoring NCT02423577?

NCT02423577 is sponsored by Autoimmune Technologies, LLC.

What drugs are being tested in NCT02423577?

Interventions in NCT02423577: FF-3 dry powder, Placebo.

Is NCT02423577 still recruiting?

NCT02423577 is currently completed. Last updated 11 August 2017.

Are results published for NCT02423577?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-08-11 · How we verify

NCT02423577

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus

Completed Phase 2 Results posted Last updated 11 August 2017

What this trial tests

Phase 2 trial testing FF-3 dry powder in Influenza in 79 participants. Completed in 1 June 2016.

Timeline

1 September 2015

Primary endpoint
1 June 2016

1 June 2016

Quick facts

Lead sponsor	Autoimmune Technologies, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	79
Start date	1 September 2015
Primary completion	1 June 2016
Estimated completion	1 June 2016
Sites	1 location across United Kingdom

Drugs / interventions tested

FF-3 dry powder — full drug profile →
Placebo

Conditions studied

Influenza — all drugs for Influenza →

Sponsor

Autoimmune Technologies, LLC — full company profile →

Who can join

Adults 18 to 50, any sex, with Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Frequencies of Viral Shedding
Time frame: Day 2 to Day 10
Percentage of Subjects Demonstrating Viral Shedding.

Sponsor's own description

The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02423577 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Autoimmune Technologies, LLC
Last refreshed: 11 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02423577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing